TEThomas Eschenhagen

Thomas Eschenhagen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thomas Eschenhagen has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiovascular Side Effects of Cancer Therapies: A Position Statement from the Heart Failure Association of the European Society of Cardiology

    by Thomas Eschenhagen, Thomas Force, Michael S. Ewer, Gilles W. de Keulenaer, Thomas M. Suter, Stefan D. Anker, Metin Avkiran, Evandro de Azambuja, Jean-Luc Balligand, Dirk L. Brutsaert, et al.

    The reductions in mortality and morbidity being achieved among cancer patients with current therapies represent a major achievement. However, given their mechanisms of action, many anti-cancer agents may have significant potential for cardiovascular side effects, including the induction of heart failure. The magnitude of this problem remains unclear and is not readily apparent from current clinical trials of emerging targeted agents, which generally under-represent older patients and those with significant co-morbidities. The risk of adverse events may also increase when novel agents, which frequently modulate survival pathways, are used in combination with each other or with other conventional cytotoxic chemotherapeutics. The extent to which survival and growth pathways in the tumour cell (which we seek to inhibit) coincide with those in cardiovascular cells (which we seek to preserve) is an open question but one that will become ever more important with the development of new cancer therapies that target intracellular signalling pathways. It remains unclear whether potential cardiovascular problems can be predicted from analyses of such basic signalling mechanisms and what pre-clinical evaluation should be undertaken. The screening of patients, optimization of therapeutic schemes, monitoring of cardiovascular function during treatment, and the management of cardiovascular side effects are likely to become increasingly important in cancer patients. This paper summarizes the deliberations of a cross-disciplinary workshop organized by the Heart Failure Association of the European Society of Cardiology (held in Brussels in May 2009), which brought together clinicians working in cardiology and oncology and those involved in basic, translational, and pharmaceutical science.


  • Open Access

    The MLCK‐mediated α 1 ‐adrenergic inotropic effect in atrial myocardium is negatively modulated by PKC ɛ signaling

    by Michael Grimm, Nina Mahnecke, Friederike Soja, Ali El‐Armouche, Pascal Haas, Hendrik Treede, Hermann Reichenspurner, Thomas Eschenhagen

    The present study examined the role of myosin light chain kinase (MLCK), PKC isozymes, and inositol 1,4,5‐trisphosphate (IP 3 ) receptor in the positive inotropic effect of α 1 ‐adrenergic stimulation in atrial myocardium. We measured inotropic effects of phenylephrine (0.3–300 μ M ) in isolated left atrial preparations (1 Hz, 37°C, 1.8 m M Ca 2+ , 0.3 μ M nadolol) from male 8‐week FVB mice ( n =200). Phenylephrine concentration‐dependently increased force of contraction from 1.5±0.1 to 2.8±0.1 m N (mean±s.e.m., n =42), which was associated with increased MLC‐2a phosphorylation at serine 21 and 22 by 67% and translocation of PKC ɛ but not PKC α to membrane (+30%) and myofilament (+50%) fractions. MLCK inhibition using ML‐7 or wortmannin right‐shifted the concentration–response curve of phenylephrine, reducing its inotropic effect at 10 μ M by 73% and 81%, respectively. The compound KIE1‐1 (500 n M ), an intracellularly acting PKC ɛ translocation inhibitor peptide, prevented PKC ɛ translocation and augmented the maximal inotropic effect of phenylephrine by 40%. In contrast, inhibition of Ca 2+ ‐dependent PKC translocation (KIC1‐1, 500 n M ) had no effect. Chelerythrine, a PKC inhibitor, decreased basal force without changing the inotropic effect of phenylephrine. The IP 3 receptor blocker 2‐APB (2 and 20 μ M ) concentration‐dependently decreased basal force, but did not affect the concentration–response curve of phenylephrine. These results indicate that activation of MLCK is required for the positive inotropic effect of α 1 ‐adrenergic stimulation, that the Ca 2+ ‐independent PKC ɛ negatively modulates this effect, and that PKC α and IP 3 receptor activation is not involved. British Journal of Pharmacology (2006) 148 , 991–1000. doi: 10.1038/sj.bjp.0706803